Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870011 | 1.00 | CYP2C19 (0.55) | CYP2C19RAB9AALDH1A1TSHRCTSC | |
| SCHEMBL23513631 | 0.87 | CYP2C19 (0.60) | CYP2C19RAB9AALDH1A1CTSCCTSK | |
| SCHEMBL5869880 | 0.85 | CYP2C19 (0.49) | CYP2C19RAB9AALDH1A1TSHRCTSC | |
| SCHEMBL8258150 | 0.85 | CYP2C19 (0.49) | CYP2C19RAB9AALDH1A1TSHRCTSC | |
| SCHEMBL7223221 | 0.85 | CYP2C19 (0.58) | CYP2C19RAB9AALDH1A1CTSCCTSK | |
| SCHEMBL5870277 | 0.85 | CYP2C19 (0.58) | CYP2C19RAB9AALDH1A1CTSCCTSK | |
| SCHEMBL5870216 | 0.83 | CYP2C19 (0.55) | CYP2C19RAB9AALDH1A1CTSCCTSK | |
| SCHEMBL8188457 | 0.80 | CYP2C19 (0.64) | CYP2C19RAB9AALDH1A1CTSCCTSK | |
| SCHEMBL14019361 | 0.80 | CYP2C19 (0.64) | CYP2C19RAB9AALDH1A1CTSCCTSK | |
| SCHEMBL5092768 | 0.79 | PKM (0.63) | RAB9AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CYP2C19 1489/4885RAB9A 2897/4885ALDH1A1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.